Your shopping cart is currently empty

EGFRvIII peptide, a synthetic peptide mirroring the EGFRvIII fusion junction—a tumor-specific, perpetually active EGFR variant missing amino acids 6-273 of the wild-type—binds to HLA-A*0201-positive T2 cells under MHC class I at 25 µg/ml. It enables antigen presentation in dendritic cells from human peripheral blood mononuclear cells (PBMCs), thus activating CD8+ cytotoxic T lymphocytes and prompting IFN-γ production. Administered at 15 µg/animal with the TLR5 agonist flagellin B, EGFRvIII peptide elevates CD8+ T cell numbers, lowers regulatory T cells (Tregs) in the brain, diminishes tumor volume, and extends survival in a GL261 glioblastoma mouse model.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $55 | Inquiry | Inquiry | |
| 5 mg | $244 | Inquiry | Inquiry | |
| 10 mg | $428 | Inquiry | Inquiry | |
| 25 mg | $939 | Inquiry | Inquiry |
| Description | EGFRvIII peptide, a synthetic peptide mirroring the EGFRvIII fusion junction—a tumor-specific, perpetually active EGFR variant missing amino acids 6-273 of the wild-type—binds to HLA-A*0201-positive T2 cells under MHC class I at 25 µg/ml. It enables antigen presentation in dendritic cells from human peripheral blood mononuclear cells (PBMCs), thus activating CD8+ cytotoxic T lymphocytes and prompting IFN-γ production. Administered at 15 µg/animal with the TLR5 agonist flagellin B, EGFRvIII peptide elevates CD8+ T cell numbers, lowers regulatory T cells (Tregs) in the brain, diminishes tumor volume, and extends survival in a GL261 glioblastoma mouse model. |
| Synonyms | PEGFRvIII (9-mer), Epidermal Growth Factor Receptor Variant III Peptide |
| Molecular Weight | 1079.20 |
| Formula | C48H78N12O16.XCF3COOH |
| Smiles | [H]N[C@@H](CC(C)C)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(NCC(N[C@@H](CC(N)=O)C(N[C@H](C(N[C@@H](C(C)C)C(O)=O)=O)CC1=CC=C(O)C=C1)=O)=O)=O)=O)=O)=O)=O.OC(C(F)(F)F)=O |
| Sequence | H-Leu-Glu-Glu-Lys-Lys-Gly-Asn-Tyr-Val-OH |
| Sequence Short | LEEKKGNYV |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||
| Solubility Information | PBS pH 7.2: 10 mg/mL (9.27 mM), Sonication is recommended. DMF: 10 mg/mL (9.27 mM), Sonication is recommended. DMSO: 10 mg/mL (9.27 mM), Sonication is recommended. | |||||||||||||||
Solution Preparation Table | ||||||||||||||||
PBS pH 7.2/DMF/DMSO
| ||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.